8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2009

BIOANALYTICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Indiana	0-23357	35-1345024
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2701 KENT AVENUE WEST LAFAYETTE, INDIANA	47906-1382
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Item 3.01.   Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 18, 2009, Bioanaltytical Systems, Inc. (the "Company") received a letter from the NASDAQ Listing Qualification Department (the "Letter") stating that the Company’s application to transfer its common shares to the Capital Market has been approved.   The transfer will occur on November 20, 2009.

The Company had previously been informed by the NASDAQ Stock Market that it did not meet minimum market value of publicly held shares and minimum bid price per share requirements.  As a result of an increase in the market value of its stock, and lower minimum market value of publicly held shares for the Capital Market, the Company is now in compliance with the Capital Market requirements.

On November 19, 2009 the Company issued a press release announcing receipt of the Letter.  A copy of that press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.    Financial Statements and Exhibits.

99.1     Bioanalytical Systems, Inc. press release, issued November 19, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Bioanalytical Systems, Inc.
Date:  November 19, 2009	By:	/s/ Michael R. Cox
		Michael R. Cox
		Vice President, Finance and Administration, Chief Financial Officer and Treasurer

Exhibit Index

Exhibit No.	Description
99.1	Bioanalytical Systems, Inc. press release, issued November 19, 2009.

EX-99.1

For more information:  Michael R. Cox

765.463.4527

mcox@BASInc.com

BASi Announces Compliance with NASDAQ Capital Markets Requirements

WEST LAFAYETTE, IN, November 19, 2009 —  Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today that its application to transfer from the NASDAQ Stock Market to the NASDAQ Capital Market has been accepted.  The transfer will occur on November 20, 2009.

The Company had previously been informed by the NASDAQ Stock Market that it did not meet minimum market value of publicly held shares and minimum bid price per share requirements.  As a result of an increase in the market value of its stock, and lower minimum market value of publicly held shares for the Capital Market, the Company is now in compliance with the Capital Market requirements.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations.  The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASInc.com for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, those market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

#  #  #  #  #